Treating non-small cell lung cancer with selumetinib: an up-to-date drug evaluation

References

• Akinleye A, Furqan M, Mukhi N, et al. MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013;6:27.
   PubMed Web of Science ®Google Scholar
• Burotto M, Chiou VL, Lee JM, et al. The MAPK pathway across different malignancies: a new perspective. Cancer. 2014;120(22):3446–3456.
   PubMed Web of Science ®Google Scholar
• Jokinen E, Koivunen JP. MEK and PI3K inhibition in solid tumors: rationale and evidence to date. Ther Adv Med Oncol. 2015;7(3):170–180.
   PubMed Web of Science ®Google Scholar
• Kim EK, Choi EJ. Compromised MAPK signaling in human diseases: an update. Arch Toxicol. 2015;89(6):867–882.
   PubMed Web of Science ®Google Scholar
• Stinchcombe TE, Johnson GL. MEK inhibition in non-small cell lung cancer. Lung Cancer. 2014;86(2):121–125.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Adjei AA. The clinical development of MEK inhibitors. Nat Rev Clin Oncol. 2014;11(7):385–400.
   PubMed Web of Science ®Google Scholar
• Sokolenko AP, Imyanitov EN. Molecular diagnostics in clinical oncology. Front Mol Biosci. 2018;5:76.
   PubMed Web of Science ®Google Scholar
• Murugan AK, Grieco M, Tsuchida N. RAS mutations in human cancers: roles in precision medicine. Semin Cancer Biol. 2019;59:23–35.
   PubMed Web of Science ®Google Scholar
• Turski ML, Vidwans SJ, Janku F, et al. Genomically driven tumors and actionability across histologies: BRAF-mutant cancers as a paradigm. Mol Cancer Ther. 2016;15(4):533–547.
   PubMed Web of Science ®Google Scholar
• Goldberg SB, Schlessinger J, Boyer JL, et al. A step towards treating KRAS-mutant NSCLC. Lancet Oncol. 2013;14(1):3–5.
   PubMed Web of Science ®Google Scholar
• Ryan MB, Corcoran RB. Therapeutic strategies to target RAS-mutant cancers. Nat Rev Clin Oncol. 2018;15(11):709–720.
   PubMed Web of Science ®Google Scholar
• McCormick F. Progress in targeting RAS with small molecule drugs. Biochem J. 2019;476(2):365–374.
   PubMed Web of Science ®Google Scholar
• Aleksakhina SN, Kashyap A, Imyanitov EN. Mechanisms of acquired tumor drug resistance. Biochim Biophys Acta Rev Cancer. 2019;1872(2):188310.
   PubMed Web of Science ®Google Scholar
• Sanchez JN, Wang T, Cohen MS. BRAF and MEK inhibitors: use and resistance in BRAF-mutated cancers. Drugs. 2018;78(5):549–566.
   PubMed Web of Science ®Google Scholar
• Tolcher AW, Peng W, Calvo E. Rational approaches for combination therapy strategies targeting the MAP Kinase pathway in solid tumors. Mol Cancer Ther. 2018;17(1):3–16.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Camidge DR, Dziadziuszko R, Peters S, et al. Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study. J Thorac Oncol. 2019 Jul;14(7):1233–1243.
   PubMed Web of Science ®Google Scholar
• Halliday PR, Blakely CM, Bivona TG. Emerging targeted therapies for the treatment of non-small cell lung cancer. Curr Oncol Rep. 2019;21(3):21.
   PubMed Web of Science ®Google Scholar
• Riely GJ, Kris MG, Rosenbaum D, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res. 2008;14(18):5731–5734.
   PubMed Web of Science ®Google Scholar
• Mitiushkina NV, Kholmatov MM, Venina AR, et al. PCR-based detection of EGFR, ALK, KRAS and BRAF mutations in Russian patients with lung adenocarcinoma: a single-center experience. Neoplasma. 2018;65(6):972–979.
   PubMed Web of Science ®Google Scholar
• Canon J, Rex K, Saiki AY, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575(7781):217–223.
   PubMed Web of Science ®Google Scholar
• Hallin J, Engstrom LD, Hargis L, et al. The KRAS(G12C)inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov. 2020;10(1):54–71.
   PubMed Web of Science ®Google Scholar
• Reck M, Rabe KF. Precision diagnosis and treatment for advanced non-small-cell lung cancer. N Engl J Med. 2017;377(9):849–861.
   PubMed Web of Science ®Google Scholar
• Ferrara MG, Di Noia V, D’Argento E, et al. Oncogene-addicted non-small-cell lung cancer: treatment opportunities and future perspectives. Cancers (Basel). 2020 May 8;12(5):E1196.
   PubMed Web of Science ®Google Scholar
• Nadal E, Massuti B, Dómine M, et al. Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors. Cancer Immunol Immunother. 2019;68(3):341–352.
   PubMed Web of Science ®Google Scholar
• Yeh TC, Marsh V, Bernat BA, et al., Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res. 2007;13(5): 1576–1583.
   PubMed Web of Science ®Google Scholar
• Ciombor KK, Bekaii-Saab T. Selumetinib for the treatment of cancer. Expert Opin Investig Drugs. 2015;24(1):111–123.
   PubMed Web of Science ®Google Scholar
• Carter CA, Rajan A, Keen C, et al. Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer. Ann Oncol. 2016;27(4):693–699.
   PubMed Web of Science ®Google Scholar
• Banerji U, Camidge D, Verheul HMW, et al. The first-in-human study of the hydrogen sulfate (Hyd-Sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res. 2010;16(5): 1613–1623.
   PubMed Web of Science ®Google Scholar
• Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13): 2139–2146.
   PubMed Web of Science ®Google Scholar
• Davies BR, Logie A, McKay JS, et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther. 2007;6(8):2209–2219.
   PubMed Web of Science ®Google Scholar
• Leijen S, Soetekouw PM, Jeffry Evans TR, et al. A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2011;68(6):1619–1628.
   PubMed Web of Science ®Google Scholar
• Tomkinson H, McBride E, Martin P, et al. Comparison of the pharmacokinetics of the phase II and phase III capsule formulations of selumetinib and the effects of food on exposure: results from two randomized crossover trials in healthy male subjects. Clin Ther. 2017;39(11):2260–2275.
   PubMed Web of Science ®Google Scholar
• Dymond AW, So K, Martin P, et al. Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials. Eur J Clin Pharmacol. 2017;73(2):175–184.
   PubMed Web of Science ®Google Scholar
• Dymond AW, Elks C, Martin P, et al. Pharmacokinetics and pharmacogenetics of the MEK1/2 inhibitor, selumetinib, in Asian and Western healthy subjects: a pooled analysis. Eur J Clin Pharmacol. 2017;73(6):717–726.
   PubMed Web of Science ®Google Scholar
• Wilky BA, Rudek MA, Ahmed S, et al. A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours. Br J Cancer. 2015;112(1):24–31.
   PubMed Web of Science ®Google Scholar
• Bridgewater J, Lopes A, Beare S, et al. A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study. BMC Cancer. 2016;16:153.
   PubMed Web of Science ®Google Scholar
• Deming DA, Cavalcante LL, Lubner SJ, et al. A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer. Invest New Drugs. 2016;34(2):168–175.
   PubMed Web of Science ®Google Scholar
• Tai WM, Yong WP, Lim C, et al. A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC). Ann Oncol. 2016;27(12):2210–2215.
   PubMed Web of Science ®Google Scholar
• Greystoke A, Steele N, Arkenau HT, et al. SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting. Br J Cancer. 2017;117(7):938–946.
   PubMed Web of Science ®Google Scholar
• Infante JR, Cohen RB, Kim KB, et al. A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors. Invest New Drugs. 2017;35(5):576–588.
   PubMed Web of Science ®Google Scholar
• LoRusso PM, Infante JR, Kim KB, et al. A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors. BMC Cancer. 2017;17(1):173.
   PubMed Web of Science ®Google Scholar
• Seto T, Hirai F, Saka H, et al. Safety and tolerability of selumetinib as a monotherapy, or in combination with docetaxel as second-line therapy, in Japanese patients with advanced solid malignancies or non-small cell lung cancer. Jpn J Clin Oncol. 2018;48(1):31–42.
   PubMed Web of Science ®Google Scholar
• Goffin JR, Nicholas G, Mates M, et al. Canadian cancer trials group (CCTG) IND215: a phase ib study of selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens. Invest New Drugs. 2019;37(3):498–506.
   PubMed Web of Science ®Google Scholar
• Holt SV, Logié A, Odedra R, et al. The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models. Br J Cancer. 2012;106(5):858–866.
   PubMed Web of Science ®Google Scholar
• Jang HY, Kim DH, Lee HJ, et al. Schedule-dependent synergistic effects of 5-fluorouracil and selumetinib in KRAS or BRAF mutant colon cancer models. Biochem Pharmacol. 2019;160:110–120.
   PubMed Web of Science ®Google Scholar
• Banerjee A, Jakacki RI, Onar-Thomas A, et al. A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a pediatric brain tumor consortium (PBTC) study. Neuro Oncol. 2017;19(8):1135–1144.
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Cebotaru CL, Kanarev V, et al. A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. J Thorac Oncol. 2010;5(10):1630–1636.
   PubMed Web of Science ®Google Scholar
• Lopez-Chavez A, Thomas A, Rajan A, et al. Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. J Clin Oncol. 2015;33(9):1000–1007.
   PubMed Web of Science ®Google Scholar
• Jänne PA, Shaw AT, Pereira JR, et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol. 2013;14(1):38–47.
   PubMed Web of Science ®Google Scholar
• Jänne PA, van den Heuvel MM, Barlesi F, et al. Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS-Mutant Advanced Non-Small Cell Lung Cancer: the SELECT-1 Randomized Clinical Trial. JAMA. 2017;317(18):1844–1853.
   PubMed Web of Science ®Google Scholar
• Stewart DJ, Kurzrock R. Cancer: the road to Amiens. J Clin Oncol. 2009;27(3):328‐333.
   Web of Science ®Google Scholar
• Del Paggio JC, Tannock IF. The fragility of phase 3 trials supporting FDA-approved anticancer medicines: a retrospective analysis. Lancet Oncol. 2019;20(8):1065‐1069.
   Web of Science ®Google Scholar
• Kurzrock R, Kantarjian HM, Kesselheim AS, et al. New drug approvals in oncology. Nat Rev Clin Oncol. 2020;17(3):140‐146.
   PubMed Web of Science ®Google Scholar
• Soria JC, Fülöp A, Maciel C, et al. SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer. Ann Oncol. 2017;28(12):3028–3036.
   PubMed Web of Science ®Google Scholar
• Lazzari C, Bulotta A, Ducceschi M, et al. Historical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer. Front Med (Lausanne). 2017;4:4.
   PubMed Web of Science ®Google Scholar
• Melosky B, Bradbury P, Tu D, et al. Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer trials group (CCTG) IND.219. Lung Cancer. 2019;133:48–55.
   PubMed Web of Science ®Google Scholar
• Oxnard GR, Yang JC, Yu H, et al. TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. Ann Oncol. 2020;31(4):507-516. 9.
   Google Scholar
• Ylli D, Van Nostrand D, Wartofsky L. Conventional radioiodine therapy for differentiated thyroid cancer. Endocrinol Metab Clin North Am. 2019;48(1):181–197.
   PubMed Web of Science ®Google Scholar
• Chakravarty D, Santos E, Ryder M, et al. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest. 2011;121(12):4700–4711.
   PubMed Web of Science ®Google Scholar
• Ho AL, Grewal RK, Leboeuf R, et al Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med. 2013;368(7):623–632.
   PubMed Web of Science ®Google Scholar
• Nagarajah J, Le M, Knauf JA, et al. Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine. J Clin Invest. 2016;126(11):4119–4124.
   PubMed Web of Science ®Google Scholar
• Rothenberg SM, McFadden DG, Palmer EL, et al. Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib. Clin Cancer Res. 2015;21(5):1028–1035.
   PubMed Web of Science ®Google Scholar
• Brose MS, Cabanillas ME, Cohen EE, et al. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17(9):1272–1282.
   PubMed Web of Science ®Google Scholar
• Song H, Zhang J, Ning L, et al. The MEK1/2 inhibitor AZD6244 sensitizes BRAF-mutant thyroid cancer to vemurafenib. Med Sci Monit. 2018;24:3002–3010.
   PubMed Web of Science ®Google Scholar
• Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol. 2018;36(1):7–13.
   PubMed Web of Science ®Google Scholar
• Leboulleux S, Dupuy C, Lacroix L, et al. Redifferentiation of a BRAFK601E-mutated poorly differentiated thyroid cancer patient with dabrafenib and trametinib treatment. Thyroid. 2019;29(5):735–742.
   PubMed Web of Science ®Google Scholar
• Wang JR, Zafereo ME, Dadu R, et al. Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAFV600E-mutated anaplastic thyroid carcinoma. Thyroid. 2019;29(8):1036–1043.
   PubMed Web of Science ®Google Scholar
• Jessen WJ, Miller SJ, Jousma E, et al. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest. 2013;123(1): 340–347.
   PubMed Web of Science ®Google Scholar
• Dombi E, Baldwin A, Marcus LJ, et al. Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N Engl J Med. 2016;375(26): 2550–2560.
   PubMed Web of Science ®Google Scholar
• Gross AM, Wolters PL, Dombi E, et al. Selumetinib in Children with Inoperable Plexiform Neurofibromas. N Engl J Med. 2020;382(15):1430–1442.
   PubMed Web of Science ®Google Scholar
• Fangusaro J, Onar-Thomas A, Young Poussaint T, et al. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncol. 2019;20(7):1011–1022.
   PubMed Web of Science ®Google Scholar
• Olow A, Mueller S, Yang X, et al. BRAF status in personalizing treatment approaches for pediatric gliomas. Clin Cancer Res. 2016;22(21):5312–5321.
   PubMed Web of Science ®Google Scholar
• Johanns TM, Ferguson CJ, Grierson PM, et al. Rapid clinical and radiographic response with combined dabrafenib and trametinib in adults with BRAF-mutated high-grade glioma. J Natl Compr Canc Netw. 2018;16(1):4–10.
   PubMed Web of Science ®Google Scholar
• Touat M, Gratieux J, Condette Auliac S, et al. Vemurafenib and cobimetinib overcome resistance to vemurafenib in BRAF-mutant ganglioglioma. Neurology. 2018;91(11):523–525.
   PubMed Web of Science ®Google Scholar
• Toll SA, Tran HN, Cotter J, et al. Sustained response of three pediatric BRAF(V600E) mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy. Oncotarget. 2019;10(4):551–557.
   PubMedGoogle Scholar
• Krauthammer M, Kong Y, Bacchiocchi A, et al. Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. Nat Genet. 2015;47(9):996–1002.
   PubMed Web of Science ®Google Scholar
• Grisham RN, Sylvester BE, Won H, et al. Extreme outlier analysis identifies occult mitogen-activated protein kinase pathway mutations in patients with low-grade serous ovarian cancer. J Clin Oncol. 2015;33(34):4099–4105.
   PubMed Web of Science ®Google Scholar
• Tentler JJ, Nallapareddy S, Tan AC, et al. Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer. Mol Cancer Ther. 2010;9(12):3351–3362.
   PubMed Web of Science ®Google Scholar
• Chen Z, Cheng K, Walton Z, et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature. 2012;483(7391):613–617.
   PubMed Web of Science ®Google Scholar
• Catalanotti F, Solit DB, Pulitzer MP, et al. Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma. Clin Cancer Res. 2013;19(8):2257–2264.
   PubMed Web of Science ®Google Scholar
• Grasso S, Tristante E, Saceda M, et al. Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation. Neoplasia. 2014;16(10):845–860.
   PubMed Web of Science ®Google Scholar
• Kaufman JM, Yamada T, Park K, et al. A transcriptional signature identifies LKB1 functional status as a novel determinant of MEK sensitivity in lung adenocarcinoma. Cancer Res. 2017;77(1):153–163.
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Bastholt L, Robert C, et al. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res. 2012;18(2):555–567.
   PubMed Web of Science ®Google Scholar
• Patel SP, Lazar AJ, Papadopoulos NE, et al. Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma. Cancer. 2013;119(4):799–805.
   PubMed Web of Science ®Google Scholar
• Planchard D, Smit EF, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017;18(10):1307–1316.
   PubMed Web of Science ®Google Scholar
• Hugo W, Zaretsky JM, Sun L, et al., Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165(1):35–44.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Ferrucci PF, Fisher R, et al. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nat Med. 2019;25(6):941–946.
   PubMed Web of Science ®Google Scholar
• Ribas A, Lawrence D, Atkinson V, et al. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. Nat Med. 2019;25(6):936–940.
   PubMed Web of Science ®Google Scholar
• Sullivan RJ, Hamid O, Gonzalez R, et al. Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. Nat Med. 2019;25(6):929–935.
   PubMed Web of Science ®Google Scholar